ADDF STATEMENT ON FDA ADVISORY COMMITTEE’S ENDORSEMENT OF LECANEMAB (LEQEMBI)
The FDA Advisory Committee’s endorsement of Leqembi ushers in a new era for Alzheimer’s therapeutics Anti-amyloids are not the panacea, underscoring the need to develop novel drugs that can be used in combination therapy approaches NEW YORK, June 9, 2023 /PRNewswire/ — Today, the FDA Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted … Read more